Neuroscience & Neuromuscular Antibody Target Library
Explore Cyagen’s Neuroscience & Neuromuscular Antibody Target Library for CNS drug delivery, neurodegenerative disease, pain and neuromuscular disorder research. Access curated target insights, fully human antibody discovery support, and translational validation solutions.
Curated CNS Target Coverage
Access key targets relevant to BBB transport, neurodegeneration, neuroinflammation, pain, and neuromuscular disease.
Fully Human Antibody Discovery
Leverage HUGO-Ab™ platforms for fully human antibody generation, screening, expression, and evaluation.
Preclinical Validation Support
Validate candidates using CNS and neuromuscular models, biomarkers, behavioral studies, and in vivo efficacy.
Product
Overview
Search our curated database to access insight reports and view Cyagen's discovery readiness for your target of interest.
| Target | Indication | Clinical Pipeline | Action |
|---|---|---|---|
| {{value.target || "--"}} | {{value.therapeutic_area || "--"}} | \ View Pipeline |
|
Next Page
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
